17321-29-8 Usage
General Description
3-Bromo-6-methoxypyridazine is a chemical compound with the molecular formula C5H5BrN2O and a molecular weight of 188.01 g/mol. It is a pyridazine derivative containing a bromine atom and a methoxy group. 3-Bromo-6-methoxypyridazine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It is known for its ability to react with various functional groups in organic chemistry, and it has been studied for its potential applications in medicinal chemistry. 3-Bromo-6-methoxypyridazine may also have other industrial uses, but its primary significance lies in its utility as a building block for the production of more complex organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 17321-29-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,7,3,2 and 1 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 17321-29:
(7*1)+(6*7)+(5*3)+(4*2)+(3*1)+(2*2)+(1*9)=88
88 % 10 = 8
So 17321-29-8 is a valid CAS Registry Number.
InChI:InChI=1/C5H5BrN2O/c1-9-5-3-2-4(6)7-8-5/h2-3H,1H3
17321-29-8Relevant articles and documents
TYK2 PSEUDOKINASE LIGANDS
-
Paragraph 0350; 0351, (2021/05/14)
Described herein are TYK2 pseudokinase ligands and methods of utilizing TYK2 pseudokinase ligands in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) BENZOHETEROARYL COMPOUNDS
-
, (2008/06/13)
This invention is directed to an (aminoiminomethyl or aminomethyl) benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.
